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Introduction
Apoptosis is a basic biological process which pro-
motes survival of the organism at the expense of indi-
vidual cells and is widely used by multi-cellular organ-
isms to remove undesirable cells [1,9,13,18,20]. Exe-
cution of the programmed death is a complex, tightly
regulated, and active cellular process whereby individ-
ual cells are triggered to undergo self-destruction in a
manner which will neither injure neighboring cells nor
elicit any inflammatory reaction [4,7,13]. Apoptosis
frequently occurs in human tumors and seems to be a
significant component of the continuous cell loss
which usually takes place during tumor development.
Techniques for measuring apoptosis are based on mor-
phological approach (light, fluorescence, and electron
microscopy), immunohistochemistry aimed to detect
apoptosis-associated proteins, and analysis of DNA
degradation (terminal transferase-mediated dUPT
nick-end labelling or TUNEL assay, in situ nick trans-
lation, and in situ hybridization for detection of DNA
strand-breaks) [11]. 
Fas (also referred to as APO-1 or CD95) is a 48-
kDa type I membrane protein, with a cysteine rich
extracellular domain of 155 amino acids, which is
expressed in various rapidly proliferating cells,
including thymocytes, immunocompetent T lympho-
cytes, epithelial cells of the skin and gut [14]. Fas
protein is a member of the tumor necrosis factor
(TNF) superfamily and mediates apoptosis when
cross-linked with agonistic anti-Fas antibody or Fas
ligand (FasL) [1,13,19,24]. Fas is a widely expressed
protein, found on the plasma membranes in most tis-
sues, including thyroid. Fas-mediated apoptosis is
thought to be involved in several inflammatory dis-
eases, autoimmune diseases and cancers [5,7
8,10,12,21,22,25]. 
Thyroid tumors represent a good model for identi-
fication of genetic changes involved in tumorigenesis.
They exhibit a stepwise progression from hyperplasia
to solitary nodule, differentiated and anaplastic carci-
noma.
Deregulation of the normal programmed cell death
mechanism plays an important role in the pathogenesis
and progression of thyroid tumors. The significance of
apoptosis in thyroid carcinoma remains basically
unknown. Our findings indicate that a broad spectrum
of neoplastically transformed cells express Fas signal
with significant variation, ranging from absent or few
scarcely positive cells to the predominantly positive
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Abstract: Using immunohistochemistry, Fas/Apo-1 protein expression was investigated in thyroid cancers of 67 patients.
Thyroid biopsies from twenty eight patients with benign thyroid diseases were also examined. The patients with thyroid can-
cer manifested a variable histology of the cancer, including 14 patients with follicular carcinoma, 48 with papillary carci-
noma, 5 patients with medullary carcinoma. The benign thyroid disease involved nodular goitre in 11 patients and follicu-
lar adenoma in other 17 patients. The study aimed at examining immunohistochemical expression of Fas protein in order to
determine whether the level of its expression correlated with histological diagnosis. In individual patients Fas expression
was more prevalent in thyroid carcinomas as compared to benign tumors (p=0.001). A marked increase in Fas expression
was found in papillary carcinoma, as compared to follicular and medullary carcinomas (p=0.02). In conclusion, Fas was sig-
nificantly more frequently overexpressed in thyroid cancer, indicating its role in thyroid tumorigenesis. 
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Materials and methods
The study was performed on samples of thyroid lesions originating
from 95 persons. The material included 28 benign lesions (11 cases
of nodular goitre [NG] and 17 cases of follicular adenoma [FA]).
In other 67 patients malignant tumors were diagnosed (14 cases of
follicular carcinoma [FC], 48 cases of papillary carcinoma [PC]
and 5 cases of medullary carcinoma [MC]). The respective paraf-
fin blocks originated from the Department of Pathological Anato-
my, University Medical School in Wroclaw and from the Depart-
ment of Pathomorphology, Lower Silesia Centre of Oncology in
Wroclaw. All the patients were subjected to surgery in the period
of 1992-2002 due to clinical symptoms of nodular goitre in the
absence of hyperthyroidism and on the basis of previous thin nee-
dle biopsy or intraoperative histopathological examination. The
type of lesions was microscopically diagnosed according to the
World Health Organisation (WHO) criteria [6]. Eighty six patients
were males and nine were females. The median age was 63.1 years
(range: 16-83 years). Before the surgery, none of the patients was
subjected to preoperative radiotherapy or chemotherapy.
Surgical specimens were fixed in 5% neutralized formalin and
embedded in paraffin according to a standard protocol. Serial 4 μm
thick sections were cut and used for routine histological examina-
tion and for immunohistochemical analysis. For histopathological
examination the sections were stained with hematoxylin and eosin.
For immunohistochemic analysis the sections were mounted on
sialinized glass slides, deparaffinized in xylene and washed in
100% alcohol. Endogenous peroxidase was blocked with 3% H2O2
for up to five minutes. The sections were washed in water and heat-
ed in mM citrate buffer (pH=6.0) for 40 min at 98°C in a water
bath. The slides were cooled to room temperature, washed in Tris
buffered saline (TBS), pH=7.6. The sections were incubated for 30
min with monoclonal mouse anti-human Fas/APO-1/CD95 anti-
body (clone: Dx2 1:500 dilution, DAKO, Denmark). After wash-
ing in TBS, pH=7.6 the signal was visualized using the catalysed
signal amplification system (CSA; K 1500 KIT; DAKO, Den-
mark), according the procedure suggested by the manufacturers.
The sections were counterstained with hematoxylin and mounted. 
In every case the Fas staining was graded in areas of normal
thyroid tissue, benign neoplasia and cancers. The staining was
scored as membranous, cytoplasmic or mainly mixed (both pat-
terns were observed in the same cell). At first under a light micro-
scope, at a low magnification (×40), the studied lesions were
screened to select regions which manifested the highest number of
apoptotic cells (hotspots). The cells were counted using ×400 mag-
nification. Fas-positive cells were quantified using Olympus BX
50 light microscope with visual mode and MultiScan 5.10 software
for computer-assisted image analysis. In every analysed case, total
numbers of thyroid cells present within the ×400 magnification
field were scored. Percentage of apoptotic cells was calculated to
yield an apoptotic index (AI=number of apoptotic thyroid cancer
cells/total number of thyroid cancer cells x 100). In every case, the
measurements were performed in 10 representative fields. 
Results were subjected to statistical analysis using Mann-
Whitney U test. For benign and malignant lesions, appropriate
mean values and standard deviations were calculated for the num-
ber of apoptotic cells. Differences at the level of p<0.05 were
regarded as statistically significant. 
Results
There was no detectable Fas immunoreactivity in nor-
mal thyroid tissue adjacent to nodular lesions nor in
the normal control specimens. The data strongly sup-
ported the notion that Fas expression occurred signifi-
cantly more often in carcinomas (Table 1). The rela-
tionship between the frequency of apoptotic cells and
the tumor histological type, classified according to
WHO criteria, is displayed in Fig 1 and 2. We have
demonstrated by immunohistochemistry that the
expression of Fas/APO-1/CD 95 has been up regulat-
ed in PC (Fig. 6a and 6b) as compared to other thyroid
carcinomas [FC, MC] (Fig. 5) and, especially, as com-
pared to benign thyroid nodular diseases [NG, FA]
(Fig. 3 and 4). Fas/APO-1/CD 95 expression has been
significantly down regulated in thyroid premalignant
lesions (Fig. 2). Increased number of Fas immunola-
belled cells has been shown in almost all cases of pap-
illary thyroid carcinomas (Fig. 1).
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Table 1. Number of patients presenting or not Fas protein expres-
sion in nodular thyroid lesions as related to histological type of the
lesion
Fig. 1. Percentage of Fas protein expression in thyroid tumors:
nodular gitre (NG), follicular adenoma (FA), follicular carcinoma
(FC), papillary carcinoma (PC), medullary carcinoma (MC). Sig-
nificant differences: PC as compared to FC and MC (*p=0.02).
Fig. 2. Percentage of Fas protein expression in benign and malig-
nant thyroid tumors. Significant differences: benign tumors as
compared to malignant tumors (*p=0.001).
Although no significant differences in apoptotic
index (AI) could be detected between the individual
thyroid histopathological processes, graphic presenta-
tion of the relationship manifested an evident dispari-
ty: the value of AI was very low in the benign thyroid
lesions [NG and FA] and definitely high in thyroid car-
cinomas [FC, PC, MC] (Fig. 1 and 2). The difference
between the benign thyroid lesions and thyroid carci-
nomas was significant (p=0.001). As expected, the
value of AI was the highest in papillary carcinoma
[PC], as compared to the other evaluated processes
(p=0.02). (Fig 1). 
Discussion
Apoptosis occurs in a variety of physiological situa-
tions, including embryogenesis; it plays a crucial role
in normal tissue homeostasis and neoplasia [7]. A
number of investigators have pointed out to the possi-
bility that a relatively low rate of apoptotic cell death
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Fig 3. Large area of nodular goiter. No one cell show positive expres-
sion of CD 95 protein (magnification ×100). Fig 4. Complete lack of
positive reaction with CD 95 antibody in follicular adenoma cells (mag-
nification ×100). Fig 5. The case of insular carcinoma. In follicular areas
is seen high expression of CD 95, the anaplastic pattern of carcinoma
shows no reaction in contrast (magnification ×200). Fig 6a. Diffuse
intense reaction with CD 95 antibody was seen in majority cases of pap-
illary thyroid carcinoma. Immunohistochemistry method stain (magnifi-
cation ×100). Fig 6b. Only focal positive reaction to CD 95 antibody in
papillary thyroid carcinoma (magnification ×200).
leads to tissue-proliferative disorders, whereas a high
rate of apoptosis leads to degenerative, tissue-degrad-
ing disorders [4,20]. Recent studies have analyzed
tumor development in terms of disordered apoptosis in
a variety of human malignancies, including thyroid
cancers [1,2,3,15,26].
In this study aberrant density of Fas expression has
been immunohistochemically detected and it has
shown quantitatively characteristic features in differ-
ent lesions. This result suggests that CD 95(Fas/Apo-
1) is a biological marker, typical of papillary thyroid
carcinoma and it allows to distinguish papillary carci-
noma from thyroid carcinoma of different histological
types. As a sensitive marker, it could reveal even
scanty foci of papillary carcinoma resistant to therapy.
In the present work, accumulation of Fas protein was
variable, often diffuse and most commonly associated
with malignant tumors of better prognosis, regardless
of the adjacent non neoplastic thyroid tissue. This phe-
nomen was confirmed in the work by Mitsiades et al.
[16], using the immunohistochemical method of Fas
labelling for the detection of apoptosis. They found
that in neoplastic tissue Fas was present in 18 of 18
papillary thyroid carcinomas. But, in contrast to our
results, they found Fas in 4 of 5 follicular, 1 of 1
anaplastic and 4 of 5 medullary carcinomas. They also
suggested that Fas expression in almost all thyroid car-
cinomas of all histological subtypes represented Fas
incapable of inducing apoptosis in these tumors. 
A similar situation was described by Arscott et al. [2].
They proved that papillary thyroid carcinoma demon-
strated very high levels of Fas expression, as compared
to the surrounding normal follicles but authors
explained this just as a non functional overexpression
of Fas. This up-regulated Fas was thought to be
induced by lymphocytic infiltrates in thyroid papillary
cancer which contained cytotoxic T lymphocytes
[CTL]. The CTL were supposed to bind to Fas, initiat-
ing the apoptotic signal [23]. The authors claimed that
Fas expression in thyroid cancers, including papillary
thyroid carcinoma, was present and functional but
overexpression of Fas was upregulated by and depend-
ent on CTL contained in the tumor. Authors of both
studies also suggested that this excessive expression of
Fas may be a consequence of early events in the devel-
opment of thyroid malignancies and suggested that
expression of Fas protein in papillary thyroid carcino-
ma had an intimate relationship in particular with this
histological type of tumor and especially with early
events of its development, potentially playing an
important role in the pathogenesis. Therefore, it was
suggested that presence of Fas alone may be insuffi-
cient to induce apoptosis in cells while upregulation of
Fas-induced apoptosis in thyroid may represent a par-
tially reversible process, more complex than thought
previously and, consequently, Fas-mediated stimula-
tion does not always result in cell death [13]. Fas can
also act as a costimulatory factor in the generation of
an immune response [1,9,20,22].
Several experimental data were carried on cancers
other than thyroid carcinomas and expression of Fas or
his ligand, FasL, was noted to be decreased in correla-
tion to the extent of malignancy in tumor cells. The
data suggested that tumor cells become resistant to
apoptosis during disease progression [2,16].
In the latest work Mitsiades et al. [15] experimen-
tally demonstrated, why expression and activation sta-
tus of Fas pathway mediator (Fas associated death
domain, procaspase 8, procaspase 9 and procaspase 3)
is always present and structurally intact in thyroid car-
cinoma cells and why it does not lead to apoptosis.
They projected interesting hypothesis that carcinoma
cells avoid Fas mediated apoptosis and also divert sig-
naling pathway from cell death to proliferation.
Fas expression in thyroid cancers has been reported
with quite variable frequencies [14]. Evaluation of
apoptosis in thyroid tumors is carried out employing a
range of techniques and the obtained results vary
extensively. Different apoptotic pathways have been
described and, therefore, numerous distinct techniques
have been used to identify apoptotic cells [4,5,14] In
assessments employing immunohistochemical evalua-
tion of Fas expression in cancers, the obtained mean
apoptotic index was significantly higher, allowing
even the use of a semiquantitative score, than in stud-
ies applying TUNEL method [17]. In this study the
estimates of apoptotic index did not exceed 2.5. Final-
ly, the studies show that evaluation of the apoptotic
index used to be complicated by technical and method-
ological problems. 
Our study also implies that possibly the upregula-
tion of Fas expression may serve as a useful biomark-
er in recognizing papillary thyroid cancer from other
types of thyroid neoplasms. Further studies, conducted
on a larger population, are needed to clarify the signif-
icance of CD 95 [Fas/Apo-1] expression in different
thyroid neoplasms.
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